Tumor Antigens for Determining Cancer Therapy
AssigneesBioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
InventorsUgur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
Claims25
A method for treating breast cancer in a patient having breast cancer, the method comprising:
- (a) determining an expression pattern of a set of tumor antigens in a sample from the patient having breast cancer, wherein the set of tumor antigens comprises CXorf61, PRAME, and CAGE1;
- (b) diagnosing the patient having breast cancer as needing a cancer therapy regimen based on the determined expression pattern of CXorf61, PRAME, and CAGE1;
- and
- (c) treating the patient having breast cancer with an immunotherapeutic that targets those tumor antigens of the set of tumor antigens expressed in the patient.
(canceled)
-9. (canceled)
(canceled)
A method for preventing or treating breast cancer in a patient comprising administering to said patient an immunotherapeutic targeting each tumor antigen of a set of tumor antigens, wherein the set of tumor antigens comprises CXorf61, PRAME, and CAGE1.
(canceled)
-21. (canceled)
A set of vaccine products comprising vaccine products for inducing an immune response against each tumor antigen of a set of tumor antigens in a patient, wherein the set of tumor antigens comprises CXorf61, PRAME, and CAGE1.
(canceled)
-33. (canceled)
Dependencies are inferred from the claim text.